Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from TARO

FDA Recalls 90,000 Children's Ibuprofen Bottles Nationwide After Consumers Report Black Particles, Gel Mass

FDA Class II recall: Nearly 90,000 bottles of children's ibuprofen by Strides Pharma contaminated with black particles. Check lot numbers 7261973A and 7261974A to ensure safety. Learn about potential health risks and next steps.

International Business Times UK

Spain's Wottan Rebbe 401 Retro-Style Naked Bike Is Perfect For the US Market

If we take a look at today’s motorcycle market, what will we notice? Well, for starters, we’ll see massive adventure bikes with way too much power and way too much tech commanding upwards of $30,000. We’ll also see a middleweight segment that’s becoming more and more infused with technology.Much to…

RideApart

3 A-Rated Pharma Stocks to Buy for Long-Term Growth

With surging medical needs, advances in precision medicine, and the adoption of generative AI, the pharmaceutical industry is thriving. Thus, it could be ideal to invest in quality pharma stocks Taro Pharmaceutical (TARO), AstraZeneca (AZN), and Merck (MRK) for long-term growth. These stocks are rated A (Strong Buy) in our…

StockNews.com

From analysis to the latest developments in health,
read the most diverse news in one place.

3 A-Rated Pharma Stocks to Boost Your Bottom Line

The pharmaceutical industry is experiencing rapid growth thanks to healthcare demand, regulatory initiatives, and technological adoption in drug discovery and development. Hence, it could be wise to invest in pharma stocks Ipsen (IPSEY), Bristol-Myers (BMY), and Taro Pharmaceutical (TARO) to drive your bottom line. These stocks are rated A (Strong…

StockNews.com

3 Top-Rated Pharma Stock Picks to Consider in the New Year

The pharmaceutical industry is expected to grow rapidly due to rising global medical needs and technological advancements. With the industry expected to thrive in the coming years, it could be wise to buy Zoetis (ZTS), AstraZeneca (AZN) and Taro Pharmaceutical (TARO) for steady returns. Read more.

StockNews.com

Pfizer Inc. (PFE) vs. Taro Pharmaceutical (TARO) - Betting on Which Pharma Stock Will Have Q4 Dominance

The pharmaceutical industry’s prospects are driven by the rising occurrence of chronic diseases coupled with the adoption of cutting-edge technology. In this context, which company among the two major industry players, Pfizer Inc. (PFE) and Taro Pharmaceutical (TARO) are going to dominate the fourth quarter? Let’s find out….

StockNews.com

Analyzing December Profit Potential for the Top 4 Pharma Stocks

The global pharmaceutical market is witnessing robust growth, fueled by an escalating demand for healthcare services amid a burgeoning and aging population. Hence, fundamentally solid pharma stocks Novartis (NVS), Bristol-Myers Squibb (BMY), AbbVie (ABBV), and Taro Pharmaceutical (TARO) might be solid buys for gains this month. Read more.

StockNews.com

Read news from The Economist, FT, and more,
with one subscription

3 High-Performing Pharma Stocks to Boost Your Portfolio

The growing adoption of innovative drugs is expected to boost the pharmaceutical industry. Therefore, it might be wise to buy fundamentally strong pharma stocks Taro Pharmaceutical (TARO), AstraZeneca (AZN) and AbbVie (ABBV) to boost your portfolio. Read on….

StockNews.com

3 Pharma Stocks Smart Money Is Following in September

With the rising prevalence of chronic diseases, the demand for pharmaceutical products is anticipated to rise. Therefore, investors could consider buying three fundamentally robust pharma stocks, Eli Lilly and Company (LLY), Zoetis (ZTS), and Taro Pharmaceutical Industries (TARO), which are gaining traction among institutional investors this month. Learn more….

StockNews.com

3 Pharma Stocks to Buy for Value Investors

The pharma industry is well-positioned to witness significant growth due to the continuous advancements in artificial intelligence and increasing demand for innovative drugs. Therefore, fundamentally strong pharma stocks Merck & Co. (MRK), Astellas Pharma (ALPMY), and Taro Pharmaceutical (TARO), which seem to be trading at a discount, might be solid…

StockNews.com

Buy These 3 Pharma Stocks in July

The pharmaceutical industry looks well-positioned for long term growth due to the globalization of the industry, increasing investments to develop life-saving drugs, rise in chronic diseases, and a rapidly aging population. To that end, it could be wise to buy fundamentally strong pharma stocks Amphastar Pharmaceuticals (AMPH), Ironwood Pharmaceuticals (IRWD),…

StockNews.com

3 Momentum Stocks Leveling Up for Profits

Amid rising fear of recession, the market is expected to remain volatile. Therefore, it could be wise for investors to buy quality stocks Taro Pharmaceutical Industries (TARO), Tennant (TNC), and Carrols Restaurant (TAST), which have soared over the past months and are leveling up for profits. Read more.

StockNews.com

5 High Growth Stocks to Buy Amid a Volatile Market

Concerns over aggressive interest rate hikes to fight the multi-decade high inflation and a looming recession have recently kept the stock market under pressure. However, growth stocks Taro Pharmaceutical (TARO), Superior Industries (SUP), Viavi Solutions (VIAV), CEVA (CEVA), and SMART Global Holdings (SGH) are well-positioned to rebound.

StockNews.com

3 Healthcare Stocks Trading Near 52-Week Lows to Buy This Month

The healthcare industry is growing rapidly amid increasing demand from an aging population and digital transformation in health systems and technologies, among other factors. And because clinical innovation is expected to continue in the healthcare sector this year, we think it could be profitable to invest in these fundamentally sound…

StockNews.com

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Taro Pharmaceutical: Q3 Earnings Insights

Taro Pharmaceutical Indus (NYSE:TARO) reported its Q3 earnings results on Thursday, January 27, 2022 at 04:00 PM. Here's what investors need to know about the announcement.

People

Dipanjan BanchurSince

722 stories

Steve Reitmeister

508 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Medical Pharmaceuticals

125 stories

AZN

104 stories

BristolMyers Squibb Company

95 stories

AstraZeneca Plc

91 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.